%0 Journal Article
%T A Combination of EGFR Inhibitors and AE-PDT Could Synergistically Suppress Breast Cancer Progression.
%A Niu Y
%A Guo X
%A Han W
%A Han X
%A Li K
%A Tian S
%A Zhu Y
%A Bai D
%A Chen Q
%J Anticancer Agents Med Chem
%V 23
%N 19
%D 2023
%M 37990592
%F 2.527
%R 10.2174/1871520623666230908145748
%X Breast cancer is the most frequently diagnosed malignancy and the leading cause of cancerrelated deaths in women. Activation of EGFR by EC-secreted EGFR ligands promotes breast cancer progression. Current treatments provide limited benefits in triple-negative breast cancer (TNBC). Photodynamic therapy (PDT) has been proven effective for the treatment of TNBC through the EGFR pathway, but the underlying mechanism is still unclear.
The purpose of this study was to determine the role of the EGFR pathway in the treatment of PDT on TNBC in a co-culture system.
MB-231 and HUVEC were co-cultured for experiments (HU-231). Cell viability and ROS production were detected after AE-PDT, a combination of EGFR inhibitors (AEE788)with PDT to test angiogenesis, apoptosis, and pyroptosis. WB detects expression of EGFR. EGFR, P-EGFR, VEGF, caspase-1, capase-3, and GSDMD .
AE-PDT inhibited HU-231 cell proliferation and tumor angiogenesis, and induced cell apoptosis and pyroptosis by promoting ROS production. AEE788, an inhibitor of the EGFR, enhanced HU-231 cell killing after AE-PDT.
Our study suggested that the combination of EGFR inhibitors and AE-PDT could synergistically suppress breast cancer progression, providing a new treatment strategy.